Healthcare ❯Pharmaceuticals

Rare Diseases

CNS Disorders Orphan Drug Designation Friedreich's Ataxia Cancer Treatments Tumor Treatments

Merck KGaA Confirms $3.9 Billion Acquisition of SpringWorks Therapeutics

The deal strengthens Merck’s oncology pipeline with two approved rare-disease therapies and is projected to boost earnings by 2027.

Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook

Biogen Acquires HI-Bio for $1.15 Billion to Enhance Immunology Pipeline